PRNewsWire
13 Oct 2026, 23:39 UTC · 1d ago
Unicycive Deadline: UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit
Impact · against what's priced in
UNCY faces potential downside as a securities fraud lawsuit alleges failure to audit manufacturing compliance, raising the risk of FDA-driven delays for oxylanthanum carbonate (OLC). The news creates uncertainty regarding the regulatory timeline for OLC's commercial launch.
- UNCY−0.40
No priced-in read yet





